ATE246677T1 - Chinolinderivate als tachykinin nk3 rezeptor antagonisten - Google Patents
Chinolinderivate als tachykinin nk3 rezeptor antagonistenInfo
- Publication number
- ATE246677T1 ATE246677T1 AT95920894T AT95920894T ATE246677T1 AT E246677 T1 ATE246677 T1 AT E246677T1 AT 95920894 T AT95920894 T AT 95920894T AT 95920894 T AT95920894 T AT 95920894T AT E246677 T1 ATE246677 T1 AT E246677T1
- Authority
- AT
- Austria
- Prior art keywords
- tachykinin
- receptor antagonists
- quinoline derivatives
- quinoline
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
- C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Manufacturing & Machinery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Ceramic Engineering (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Structural Engineering (AREA)
- Diabetes (AREA)
- Materials Engineering (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT94MI001099A ITMI941099A1 (it) | 1994-05-27 | 1994-05-27 | Derivati chinolinici |
IT95MI000494 IT1293558B1 (it) | 1995-03-14 | 1995-03-14 | Derivati chinolinici |
PCT/EP1995/002000 WO1995032948A1 (en) | 1994-05-27 | 1995-05-23 | Quinoline derivatives as tachykinin nk3 receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE246677T1 true ATE246677T1 (de) | 2003-08-15 |
Family
ID=26331143
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98204483T ATE273959T1 (de) | 1994-05-27 | 1995-05-23 | Chinolinderivate als tachykinin nk3 rezeptor antagonisten |
AT95920894T ATE246677T1 (de) | 1994-05-27 | 1995-05-23 | Chinolinderivate als tachykinin nk3 rezeptor antagonisten |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98204483T ATE273959T1 (de) | 1994-05-27 | 1995-05-23 | Chinolinderivate als tachykinin nk3 rezeptor antagonisten |
Country Status (35)
Country | Link |
---|---|
US (5) | US6608083B1 (de) |
EP (2) | EP0940391B1 (de) |
JP (5) | JP3664492B2 (de) |
KR (1) | KR100316571B1 (de) |
CN (3) | CN1092642C (de) |
AP (1) | AP578A (de) |
AR (1) | AR037069A2 (de) |
AT (2) | ATE273959T1 (de) |
AU (1) | AU699319B2 (de) |
BG (2) | BG64004B1 (de) |
BR (1) | BR9507788A (de) |
CA (1) | CA2191352C (de) |
CZ (1) | CZ291476B6 (de) |
DE (2) | DE69533408T2 (de) |
DK (1) | DK0804419T3 (de) |
DZ (1) | DZ1889A1 (de) |
ES (2) | ES2204952T3 (de) |
FI (2) | FI115052B (de) |
HK (2) | HK1003884A1 (de) |
HU (1) | HU226535B1 (de) |
IL (1) | IL113844A (de) |
MA (1) | MA23560A1 (de) |
MX (1) | MX9605903A (de) |
MY (1) | MY129596A (de) |
NO (2) | NO307783B1 (de) |
NZ (1) | NZ287442A (de) |
OA (1) | OA10592A (de) |
PL (2) | PL186665B1 (de) |
PT (2) | PT940391E (de) |
RO (1) | RO114445B1 (de) |
SA (1) | SA95160290B1 (de) |
SK (2) | SK282721B6 (de) |
TW (2) | TW533199B (de) |
UA (1) | UA51623C2 (de) |
WO (1) | WO1995032948A1 (de) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2191352C (en) | 1994-05-27 | 2001-01-30 | Carlo Farina | Quinoline derivatives as tachykinin nk3 receptor antagonists |
AU757836B2 (en) * | 1995-11-24 | 2003-03-06 | Smithkline Beecham Spa | Quinoline derivatives |
GB9524104D0 (en) * | 1995-11-24 | 1996-01-24 | Smithkline Beecham Spa | Novel compounds |
GB9524137D0 (en) | 1995-11-24 | 1996-01-24 | Smithkline Beecham Spa | Novel compounds |
AR004735A1 (es) * | 1995-11-24 | 1999-03-10 | Smithkline Beecham Spa | Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento. |
WO1997021680A1 (en) * | 1995-11-24 | 1997-06-19 | Smithkline Beecham S.P.A. | Quinoline derivatives |
US6100267A (en) * | 1997-03-14 | 2000-08-08 | Smithkline Beecham Corporation | Quinoline- and naphthalenecarboxamides, pharmaceutical compositions and methods of inhibiting calpain |
US6077850A (en) * | 1997-04-21 | 2000-06-20 | G.D. Searle & Co. | Substituted benzopyran analogs for the treatment of inflammation |
US20010012846A1 (en) * | 1997-05-23 | 2001-08-09 | Glardina Giuseppe Arnaldo Maria | Quinoline-4-carboxamide derivatives as NK-2 and NK-3 receptor antagonists |
WO1998052942A1 (en) * | 1997-05-23 | 1998-11-26 | Smithkline Beecham S.P.A. | Quinoline-4-carboxamide derivatives as nk-2 and nk-3 receptor antagonists |
AP1201A (en) * | 1997-09-17 | 2003-09-01 | Smithkline Beecham Corp | Method for the synthesis of quinoline derivatives. |
EP1652840A3 (de) * | 1997-09-17 | 2006-05-17 | Smithkline Beecham Corporation | (-)-(S)-N-(.alpha.-Ethylbenzyl)-3-hydroxy-2-phenylchinolin-4-carboxamid |
US6083944A (en) * | 1997-10-07 | 2000-07-04 | Cephalon, Inc. | Quinoline-containing α-ketoamide cysteine and serine protease inhibitors |
KR20010075726A (ko) * | 1998-11-20 | 2001-08-09 | 파올로 비지, 엔리꼬 카쭐라니 | Nk-3 및 nk-2 수용체 길항제로서의퀴놀린-4-카르복스아미드 유도체 |
US6780875B2 (en) * | 1998-11-20 | 2004-08-24 | Smithkline Beecham S.P.A. | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists |
GB9825554D0 (en) | 1998-11-20 | 1999-01-13 | Smithkline Beecham Spa | Novel Compounds |
DE60018707T2 (de) * | 1999-01-25 | 2006-02-09 | Smithkline Beecham Corp. | Anti-androgene und verfahren zur behandlung von krankheiten |
US7037922B1 (en) * | 2000-03-10 | 2006-05-02 | Neurogen Corporation | Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands |
JP2002540203A (ja) | 1999-03-29 | 2002-11-26 | ニューロゲン コーポレイション | Nk−3および/またはgaba(a)受容体リガンドとしての4−置換キノリン誘導体 |
AU4802500A (en) | 1999-04-26 | 2000-11-10 | Neurogen Corporation | 2-aminoquinolinecarboxamides: neurokinin receptor ligands |
US6521618B2 (en) | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
AU2001276556A1 (en) * | 2000-08-11 | 2002-02-25 | Smithkline Beecham P.L.C. | Novel pharmaceutical use of quinnoline derivatives |
GB0028964D0 (en) * | 2000-11-28 | 2001-01-10 | Smithkline Beecham Spa | Novel compounds |
US6540733B2 (en) * | 2000-12-29 | 2003-04-01 | Corazon Technologies, Inc. | Proton generating catheters and methods for their use in enhancing fluid flow through a vascular site occupied by a calcified vascular occlusion |
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
ATE313539T1 (de) * | 2001-04-11 | 2006-01-15 | Glaxosmithkline Spa | Chinolin-4-carboxamidderivate als nk-3 und nk-2 rezeptor antagonisten |
US20040152727A1 (en) * | 2001-05-18 | 2004-08-05 | Hay Douglas William Pierre | Novel use |
AU2003244080A1 (en) * | 2002-06-26 | 2004-01-19 | Kyowa Hakko Kogyo Co., Ltd. | Phosphodiesterase inhibitor |
GB0228288D0 (en) * | 2002-12-04 | 2003-01-08 | Smithkline Beecham Corp | Chemical compounds |
GB0228287D0 (en) * | 2002-12-04 | 2003-01-08 | Smithkline Beecham Corp | Chemical compounds |
GB0312609D0 (en) | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
SE0302139D0 (sv) * | 2003-07-28 | 2003-07-28 | Astrazeneca Ab | Novel compounds |
PL1711530T3 (pl) | 2003-12-22 | 2010-01-29 | Glaxo Group Ltd | Immunoglobuliny neutralizujące Nogo-A do leczenia chorób neurologicznych |
WO2005080373A1 (en) | 2004-02-04 | 2005-09-01 | Pfizer Products Inc. | Substituted quinoline compounds |
EP1729751A1 (de) * | 2004-03-25 | 2006-12-13 | Smithkline Beecham Corporation | Verwendung eines nk3-antagonisten zur behandlung von bipolaren störungen |
RU2006138054A (ru) * | 2004-03-30 | 2008-05-10 | Смиткайн Бичам Корпорейшн (Us) | Высушенные распылением фармацевтические композиции |
US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
MX341797B (es) | 2004-06-24 | 2016-09-02 | Vertex Pharmaceuticals Incorporated * | Moduladores de transportadores con casete de union con atp. |
GB0417560D0 (en) * | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Therapeutic compounds |
GB0417559D0 (en) * | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Therapeutic compounds |
GB0425075D0 (en) * | 2004-11-12 | 2004-12-15 | Smithkline Beecham Corp | Novel compounds |
GB0425077D0 (en) * | 2004-11-12 | 2004-12-15 | Smithkline Beecham Corp | Novel compounds |
GB0425076D0 (en) * | 2004-11-12 | 2004-12-15 | Smithkline Beecham Corp | Novel compounds |
GB0428233D0 (en) * | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Compounds |
EP1891012A2 (de) * | 2005-06-03 | 2008-02-27 | AstraZeneca AB | Chinolinderivate als nk3-antagonisten |
WO2006137789A1 (en) * | 2005-06-23 | 2006-12-28 | Astrazeneca Ab | Quinoline 3 -sulfonate esters as NK3 receptor modulators |
GB0515580D0 (en) | 2005-07-29 | 2005-09-07 | Merck Sharp & Dohme | Therapeutic compounds |
JP2009504572A (ja) * | 2005-08-02 | 2009-02-05 | スミスクライン・ビーチャム・コーポレイション | キノリン誘導体の合成方法 |
EP1915363A1 (de) * | 2005-08-11 | 2008-04-30 | AstraZeneca AB | Oxopyridylchinolinamide als modulatoren des nk3-rezeptors |
WO2007018465A1 (en) * | 2005-08-11 | 2007-02-15 | Astrazeneca Ab | Amide alkyl pyridiyl quinolines as nk3 receptor modulators |
AR058051A1 (es) * | 2005-09-21 | 2008-01-23 | Astrazeneca Ab | Quinolinas de alquilnitrilo.proceso de obtencion y composiciones farmaceuticas. |
WO2007035156A1 (en) * | 2005-09-21 | 2007-03-29 | Astrazeneca Ab | N-oxo-heterocycle and n-oxo-alkyl quinoline-4-carboxamides as nk-3 receptor ligands |
AR057130A1 (es) | 2005-09-21 | 2007-11-14 | Astrazeneca Ab | Quinolinas de alquilsulfoxido y una composicion farmaceutica |
TW201018662A (en) * | 2005-12-12 | 2010-05-16 | Astrazeneca Ab | Alkylsulphonamide quinolines |
GB0525662D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
AU2006331614A1 (en) * | 2005-12-24 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Quinolin- 4 - one derivatives as modulators of ABC transporters |
US20110064811A1 (en) | 2005-12-28 | 2011-03-17 | Patricia Hurter | Solid forms of N-[2,4-BIS(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
EP1981882A4 (de) * | 2006-01-27 | 2009-11-18 | Astrazeneca Ab | Amidsubstituierte chinoline |
GB0603087D0 (en) * | 2006-02-15 | 2006-03-29 | Glaxo Group Ltd | Novel use |
MX2009010059A (es) | 2007-03-22 | 2009-10-12 | Astrazeneca Ab | Derivados de quinolina para el tratamiento de enfermedades inflamatorias. |
US8173639B2 (en) | 2007-04-26 | 2012-05-08 | H. Lundbeck A/S | Isoquinolinone derivatives as NK3 antagonists |
WO2008131779A1 (en) * | 2007-04-26 | 2008-11-06 | H. Lundbeck A/S | Isoquinolinone derivatives as nk3 antagonists |
EP2559686A1 (de) * | 2007-08-22 | 2013-02-20 | Allergan, Inc. | Therapeutische Chinolin- und Naphthalinderivate |
WO2009049791A2 (en) * | 2007-10-15 | 2009-04-23 | F. Hoffmann-La Roche Ag | Radiolabeled nk3 receptor antagonist |
PE20091036A1 (es) | 2007-11-30 | 2009-08-15 | Astrazeneca Ab | Derivado de quinolina como antagonista del receptor p2x7 |
CN102123998A (zh) | 2008-06-23 | 2011-07-13 | H.隆德贝克有限公司 | 作为nk3拮抗剂的异喹啉酮衍生物 |
US8242134B2 (en) | 2008-09-15 | 2012-08-14 | H. Lundbeck A/S | Isoquinolinone derivatives as NK3 antagonists |
KR20110070985A (ko) | 2008-10-20 | 2011-06-27 | 하. 룬드벡 아크티에셀스카브 | Nk3 길항제로서의 이소퀴놀리논 유도체 |
MX2011009867A (es) | 2009-03-20 | 2012-01-12 | Vertex Pharma | Proceso para producir moduladores del regulador de conductancia transmembrana de fibrosis quistica. |
TW201143768A (en) | 2009-12-15 | 2011-12-16 | Lundbeck & Co As H | Pyridone derivatives as NK3 antagonists |
TW201144311A (en) | 2010-03-12 | 2011-12-16 | Lundbeck & Co As H | Azaisoquionolinone derivatives as NK3 antagonists |
US8487102B2 (en) * | 2010-04-20 | 2013-07-16 | Hoffmann-La Roche Inc. | Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists |
US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
US9346814B2 (en) | 2012-01-17 | 2016-05-24 | Universiteit Antwerp | FAP inhibitors |
CN109966264A (zh) | 2012-02-27 | 2019-07-05 | 沃泰克斯药物股份有限公司 | 药物组合物及其施用 |
CN102702099A (zh) * | 2012-06-21 | 2012-10-03 | 江苏恩华药业股份有限公司 | (s)-3-羟基-2-苯基-n-(1-苯基丙基)喹啉-4-甲酰胺的制备方法 |
BR112015026519A2 (pt) | 2013-04-19 | 2017-07-25 | Astrazeneca Ab | composto antagonista do receptor nk3 (nk3ra) para uso em um método destinado ao tratamento de síndrome do ovário policístico (sop) |
WO2015200594A2 (en) | 2014-06-25 | 2015-12-30 | Emory University | Methods of managing conditioned fear with neurokinin receptor antagonists |
WO2016004035A1 (en) * | 2014-07-01 | 2016-01-07 | Icahn School Of Medicine At Mount Sinai | 2-aryl-4-quinolinecarboxamide derivatives for treating thyroid diseases |
WO2016037954A1 (de) | 2014-09-09 | 2016-03-17 | Bayer Pharma Aktiengesellschaft | Substituierte n,2-diarylchinolin-4-carboxamide und ihre anti-inflammatorische verwendung |
EP3204358B1 (de) | 2014-10-07 | 2018-09-19 | Vertex Pharmaceuticals Incorporated | Cokristalle von modulatoren des transmembrankonduktanzregulators bei zystischer fibrose |
EP3271334A1 (de) | 2015-03-18 | 2018-01-24 | Bayer Pharma Aktiengesellschaft | Substituierte n-bicyclo-2-arylchinolin-4-carboxamide und ihre verwendung |
RU2743206C2 (ru) * | 2015-05-18 | 2021-02-16 | Кэнди Терапьютикс Лимитед | Двойные антагонисты рецептора нейрокинин-1/нейрокинин-3 для лечения заболеваний, зависимых от половых гормонов |
WO2017072629A1 (en) | 2015-10-29 | 2017-05-04 | Cadila Healthcare Limited | Pharmaceutical combination of nk3 receptor antagonist and biguanides |
WO2017153235A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-3-aryl-1-naphthamide und ihre verwendung |
WO2017153234A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-2-arylchinolin-4-carboxamide und ihre verwendung |
WO2017153231A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-2-arylisochinolinon-4-carboxamide und ihre verwendung |
CN105884626B (zh) * | 2016-05-04 | 2017-10-20 | 龙曦宁(上海)医药科技有限公司 | 一种2‑氨基茚满衍生物的合成方法及其产品 |
TWI770157B (zh) | 2017-04-10 | 2022-07-11 | 德商拜耳廠股份有限公司 | 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途 |
CN110730776A (zh) | 2017-04-10 | 2020-01-24 | 拜耳股份公司 | 取代的n-芳基乙基-2-芳基喹啉-4-甲酰胺及其用途 |
EP3704271A4 (de) | 2017-11-02 | 2021-09-08 | California Institute of Technology | Neurokinin-antagonisten und verwendung davon |
CN113194948A (zh) * | 2018-11-15 | 2021-07-30 | 国立大学法人九州大学 | Il-31介导性疾病的预防或治疗剂及医药组合物 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1560489A (en) * | 1976-05-21 | 1980-02-06 | Fisons Ltd | Pharmaceutical compositions |
FR2538388B1 (fr) | 1982-12-24 | 1985-06-21 | Pharmuka Lab | Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments |
DE3905339A1 (de) * | 1989-02-22 | 1990-09-06 | Basf Ag | Chinolin-4-carbonsaeurederivate und deren verwendung |
US4992448A (en) * | 1989-10-24 | 1991-02-12 | Hoechst-Roussel Pharmaceuticals Inc. | Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders |
US5037835A (en) * | 1989-10-24 | 1991-08-06 | Hoechst-Roussel Pharmaceuticals Inc. | Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders |
EP0449565B1 (de) * | 1990-03-26 | 1997-05-14 | Matsushita Electric Industrial Co., Ltd. | Lichtempfindliches Material für Elektrophotographie |
DE69315920T2 (de) * | 1992-09-04 | 1998-06-10 | Takeda Chemical Industries Ltd | Kondensierte heterozyklische Verbindungen, deren Herstellung und Verwendung |
US5434158A (en) * | 1994-04-26 | 1995-07-18 | Merck & Co., Inc. | Spiro-substituted azacycles as neurokinin-3 antagonists |
CA2191352C (en) * | 1994-05-27 | 2001-01-30 | Carlo Farina | Quinoline derivatives as tachykinin nk3 receptor antagonists |
US5607936A (en) * | 1994-09-30 | 1997-03-04 | Merck & Co., Inc. | Substituted aryl piperazines as neurokinin antagonists |
-
1995
- 1995-05-23 CA CA002191352A patent/CA2191352C/en not_active Expired - Fee Related
- 1995-05-23 NZ NZ287442A patent/NZ287442A/en not_active IP Right Cessation
- 1995-05-23 HU HU9603262A patent/HU226535B1/hu not_active IP Right Cessation
- 1995-05-23 UA UA96124918A patent/UA51623C2/uk unknown
- 1995-05-23 AT AT98204483T patent/ATE273959T1/de not_active IP Right Cessation
- 1995-05-23 SK SK1514-96A patent/SK282721B6/sk not_active IP Right Cessation
- 1995-05-23 AT AT95920894T patent/ATE246677T1/de not_active IP Right Cessation
- 1995-05-23 WO PCT/EP1995/002000 patent/WO1995032948A1/en active IP Right Grant
- 1995-05-23 CZ CZ19963470A patent/CZ291476B6/cs not_active IP Right Cessation
- 1995-05-23 BR BR9507788A patent/BR9507788A/pt not_active IP Right Cessation
- 1995-05-23 PT PT98204483T patent/PT940391E/pt unknown
- 1995-05-23 PL PL95341889A patent/PL186665B1/pl not_active IP Right Cessation
- 1995-05-23 AU AU26164/95A patent/AU699319B2/en not_active Ceased
- 1995-05-23 ES ES95920894T patent/ES2204952T3/es not_active Expired - Lifetime
- 1995-05-23 ES ES98204483T patent/ES2227769T3/es not_active Expired - Lifetime
- 1995-05-23 PT PT95920894T patent/PT804419E/pt unknown
- 1995-05-23 DE DE69533408T patent/DE69533408T2/de not_active Expired - Lifetime
- 1995-05-23 CN CN95194338A patent/CN1092642C/zh not_active Expired - Fee Related
- 1995-05-23 EP EP98204483A patent/EP0940391B1/de not_active Expired - Lifetime
- 1995-05-23 JP JP50028796A patent/JP3664492B2/ja not_active Expired - Fee Related
- 1995-05-23 DE DE69531458T patent/DE69531458T2/de not_active Expired - Lifetime
- 1995-05-23 PL PL95317381A patent/PL186075B1/pl not_active IP Right Cessation
- 1995-05-23 KR KR1019960706701A patent/KR100316571B1/ko not_active IP Right Cessation
- 1995-05-23 SK SK47-99A patent/SK282722B6/sk not_active IP Right Cessation
- 1995-05-23 EP EP95920894A patent/EP0804419B1/de not_active Expired - Lifetime
- 1995-05-23 RO RO96-02234A patent/RO114445B1/ro unknown
- 1995-05-23 DK DK95920894T patent/DK0804419T3/da active
- 1995-05-24 DZ DZ950061A patent/DZ1889A1/fr active
- 1995-05-24 AP APAP/P/1995/000745A patent/AP578A/en active
- 1995-05-25 MA MA23898A patent/MA23560A1/fr unknown
- 1995-05-25 US US08/450,437 patent/US6608083B1/en not_active Expired - Fee Related
- 1995-05-25 IL IL11384495A patent/IL113844A/xx not_active IP Right Cessation
- 1995-05-25 US US08/450,438 patent/US5811553A/en not_active Expired - Lifetime
- 1995-05-25 MY MYPI95001381A patent/MY129596A/en unknown
- 1995-05-26 TW TW088121625A patent/TW533199B/zh not_active IP Right Cessation
- 1995-05-26 TW TW084105319A patent/TW427977B/zh not_active IP Right Cessation
- 1995-10-03 SA SA95160290A patent/SA95160290B1/ar unknown
-
1996
- 1996-11-25 BG BG101008A patent/BG64004B1/bg unknown
- 1996-11-26 FI FI964712A patent/FI115052B/fi active IP Right Grant
- 1996-11-26 NO NO965036A patent/NO307783B1/no unknown
- 1996-11-26 MX MX9605903A patent/MX9605903A/es not_active IP Right Cessation
- 1996-11-27 OA OA60928A patent/OA10592A/en unknown
-
1998
- 1998-04-09 HK HK98103021A patent/HK1003884A1/xx not_active IP Right Cessation
-
1999
- 1999-01-15 CN CN99100978A patent/CN1276211A/zh active Pending
- 1999-02-10 FI FI990268A patent/FI119721B/fi active IP Right Grant
- 1999-02-16 BG BG103181A patent/BG103181A/bg unknown
- 1999-04-16 NO NO991813A patent/NO326714B1/no unknown
- 1999-06-18 JP JP11172597A patent/JP2000026314A/ja active Pending
-
2000
- 2000-03-06 HK HK00101401A patent/HK1024469A1/xx not_active IP Right Cessation
- 2000-06-22 AR ARP000103117A patent/AR037069A2/es unknown
-
2001
- 2001-05-29 US US09/867,133 patent/US20030236281A1/en not_active Abandoned
- 2001-10-24 JP JP2001326622A patent/JP2002179594A/ja active Pending
-
2002
- 2002-03-18 CN CN02107941A patent/CN1428145A/zh active Pending
-
2004
- 2004-09-30 JP JP2004287629A patent/JP2005068155A/ja active Pending
- 2004-11-29 US US10/999,180 patent/US20050096316A1/en not_active Abandoned
-
2006
- 2006-03-21 US US11/385,461 patent/US7482458B2/en not_active Expired - Fee Related
- 2006-12-28 JP JP2006355694A patent/JP2007126475A/ja not_active Ceased
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE273959T1 (de) | Chinolinderivate als tachykinin nk3 rezeptor antagonisten | |
DE69728392D1 (de) | Indolderivate verwendbar als endothelinrezeptorantagonisten | |
NO951613D0 (no) | Ikke-peptidyl tachykinin reseptorantagonister | |
CY2505B1 (en) | Quinoline derivatives as nk3 antagonists | |
DE69531331D1 (de) | Phenylpiperidinderivate als neurokinin antagonists | |
DE69734833D1 (de) | Vitronektin rezeptor antagonisten | |
ATE187172T1 (de) | Chinolin-2-on derivate als serotonin antagonisten | |
ATE221052T1 (de) | Tetrahydrochinolinderivate als eaa antagonisten | |
DE69626220D1 (de) | 3-azetidinylalkylpiperidine oder -pyrrolidine als tachykinin antagonisten | |
ATE286022T1 (de) | Naphthalin-carboxamide als tachykinin rezeptorantagonisten | |
ATE233243T1 (de) | Salze von chinolinderivaten als nk3 antagonisten | |
DE69703242D1 (de) | Indolin-derivate verwendbar als 5-ht-2c rezeptor-antagonisten | |
ID24468A (id) | 2-asilaminopropanamina sebagai antagonis reseptor tachykinin | |
DE69735811D1 (de) | Piperazinoderivate als neurokinin-antagonisten | |
DE69717449T2 (de) | Indolin-derivate verwendbar als 5-ht-2c rezeptor-antagonisten | |
ATE206421T1 (de) | Heterocyclisch substituierte piperazonderivate als tachykinin rezeptor antagonisten | |
ATE208764T1 (de) | Isazole derivate als fibrinogen-rezeptor- antagonisten | |
ID24309A (id) | 2-asilaminopropanamina sebagai antagonis reseptor tachykinin | |
DK0940391T3 (da) | Quinolinderivater som tachykinin-NK3-receptor-antagonister | |
DE69714019T2 (de) | 1,4-dihydropyridin-verbindungen als bradykinin-antagonisten | |
SI0940391T1 (en) | Quinoline derivatives as tachykinin NK3 receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0804419 Country of ref document: EP |
|
EEIH | Change in the person of patent owner | ||
REN | Ceased due to non-payment of the annual fee |